The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen) and Aduhelm (aducanumab). They are used for Duchenne muscular dystrophy and Alzheimer's disease.

Viking Therapeutics announced the start of Phase 3 studies involving its injectable, GLP-1/GIP-targeted obesity drug, called ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Biogen’s Aduhelm, Sarepta’s Exondys 51, along with Covis Pharma’s Makena were all cleared quickly by the US Food and Drug Administration despite weak evidence and disagreements among reviewers, ...

Sarepta said it is "fully committed" to completing the trial for Exondys and attributes the delays to a variety of factors including ... Biogen Inc.'s Alzheimer's drug Aduhelm may be the best ...

Early last year, Biogen pulled the plug on the treatment. Biogen FDA Office of Inspector General (OIG) Department of Health and Human Services (HHS) accelerated approval Sarepta Makena Exondys 51 ...

Sarepta said continued approval of the gene therapy may hinge on evidence from a ... But it drew criticism in 2021 after the FDA cleared Biogen’s controversial Alzheimer’s drug ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Crispr Therapeutics AG (CRSP – Research Report ...

The Sarepta and Biogen therapies mentioned are, respectively, Exondys 51 (eteplirsen) and Aduhelm (aducanumab). They are used for Duchenne muscular dystrophy and Alzheimer's disease.

Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed approval for drugs to fill unmet needs, federal watchdogs said in a report.